Possible Bearish Signals With BioMarin Pharmaceutical Insiders Disposing Stock
Possible Bearish Signals With BioMarin Pharmaceutical Insiders Disposing Stock
Many BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) insiders ditched their stock over the past year, which may be of interest to the company's shareholders. When evaluating insider transactions, knowing whether insiders are buying versus if they selling is usually more beneficial, as the latter can be open to many interpretations. However, when multiple insiders sell stock over a specific duration, shareholders should take notice as that could possibly be a red flag.
在過去的一年中,許多BioMarin製藥公司(納斯達克股票代碼:BMRN)內部人士拋售了股票,這可能會引起該公司的股東的興趣。在評估內幕交易時,了解內部人士是買入還是賣出通常更有利,因爲後者可能有多種解釋。但是,當多個內部人士在特定期限內出售股票時,股東應注意,因爲這可能是一個危險信號。
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.
儘管我們絕不會建議投資者僅根據公司董事的所作所爲做出決定,但我們確實認爲密切關注內部人士的所作所爲是完全合乎邏輯的。
View our latest analysis for BioMarin Pharmaceutical
查看我們對BioMarin Pharmace的最新分析
BioMarin Pharmaceutical Insider Transactions Over The Last Year
BioMarin Pharmaceutical在過去一年的內幕交易
The President of Worldwide Research & Development, Henry Fuchs, made the biggest insider sale in the last 12 months. That single transaction was for US$1.1m worth of shares at a price of US$90.43 each. That means that even when the share price was below the current price of US$93.61, an insider wanted to cash in some shares. We generally consider it a negative if insiders have been selling, especially if they did so below the current price, because it implies that they considered a lower price to be reasonable. Please do note, however, that sellers may have a variety of reasons for selling, so we don't know for sure what they think of the stock price. We note that the biggest single sale was only 6.4% of Henry Fuchs's holding.
全球研發總裁亨利·福克斯進行了過去12個月中最大規模的內幕交易。這筆單筆交易是價值110萬美元的股票,每股價格爲90.43美元。這意味着,即使股價低於當前的93.61美元,內部人士也想套現部分股票。如果內部人士一直在賣出,特別是如果他們賣出低於當前價格,我們通常認爲這是負數,因爲這意味着他們認爲較低的價格是合理的。但是,請注意,賣家可能有各種各樣的賣出原因,因此我們不確定他們對股價的看法。我們注意到,最大的單筆銷售僅佔亨利·福克斯持股量的6.4%。
BioMarin Pharmaceutical insiders didn't buy any shares over the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!
去年,BioMarin Pharmaceutical的內部人士沒有購買任何股票。你可以在下面看到過去 12 個月的內幕交易(公司和個人)的直觀描述。通過點擊下面的圖表,你可以看到每筆內幕交易的確切細節!
![insider-trading-volume](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231206/0-20f6f503197b37b244b88860ff2504c9-0-12845961fc94b09b9f5703613ac88b8a.png/big)
I will like BioMarin Pharmaceutical better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.
如果我看到一些大規模的內幕買入,我會更喜歡BioMarin Pharmaceutical的。在我們等待的同時,請查看這份免費名單,列出了最近有大量內幕買入的成長型公司。
Insider Ownership Of BioMarin Pharmaceutical
BioMarin製藥的內部所有權
For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. BioMarin Pharmaceutical insiders own about US$120m worth of shares (which is 0.7% of the company). Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.
對於普通股股東來說,值得檢查一下公司內部人士持有多少股票。我們通常希望看到相當高的內部所有權。BioMarin Pharmaceutical內部人士擁有價值約1.2億美元的股份(佔該公司的0.7%)。大多數股東會很高興看到這種內部所有權,因爲這表明管理層的激勵措施與其他股東非常一致。
So What Does This Data Suggest About BioMarin Pharmaceutical Insiders?
那麼,這些數據對BioMarin製藥業內部人士有何啓示呢?
There haven't been any insider transactions in the last three months -- that doesn't mean much. While we feel good about high insider ownership of BioMarin Pharmaceutical, we can't say the same about the selling of shares. Therefore, you should definitely take a look at this FREE report showing analyst forecasts for BioMarin Pharmaceutical.
在過去的三個月中,沒有任何內幕交易——這並不意味着什麼。儘管我們對BioMarin Pharmaceutical的高內部所有權感到滿意,但我們不能對股票的出售說同樣的話。因此,你一定要看看這份免費報告,該報告顯示了分析師對BioMarin Pharmaceutical的預測。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
當然,通過尋找其他地方,你可能會找到一筆不錯的投資。因此,來看看這份有趣的公司的免費清單吧。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,內部人士是那些向相關監管機構報告交易的個人。我們目前僅對公開市場交易和直接權益的私人處置進行覈算,但不包括衍生品交易或間接權益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St 的這篇文章本質上是籠統的。我們僅使用公正的方法提供基於歷史數據和分析師預測的評論,我們的文章並非旨在提供財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不會考慮最新的價格敏感型公司公告或定性材料。華爾街只是沒有持有上述任何股票的頭寸。